Knowledge of tumor/blood genomic testing (NGS) and ESR1 mutations in a survey of patients with ER+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Meisel, Jane
Sammons, Sarah L.
Shanahan, Kelly
Pluard, Timothy
Kozlowski, Monica
Carroll, Dominic
Attias, Elizabeth
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-09-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-09-02
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
    Spoerke, Jill M.
    Gendreau, Steven
    Walter, Kimberly
    Qiu, Jiaheng
    Wilson, Timothy R.
    Savage, Heidi
    Aimi, Junko
    Derynck, Mika K.
    Chen, Meng
    Chan, Iris T.
    Amler, Lukas C.
    Hampton, Garret M.
    Johnston, Stephen
    Krop, Ian
    Schmid, Peter
    Lackner, Mark R.
    NATURE COMMUNICATIONS, 2016, 7
  • [42] Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
    Jill M. Spoerke
    Steven Gendreau
    Kimberly Walter
    Jiaheng Qiu
    Timothy R. Wilson
    Heidi Savage
    Junko Aimi
    Mika K. Derynck
    Meng Chen
    Iris T. Chan
    Lukas C. Amler
    Garret M. Hampton
    Stephen Johnston
    Ian Krop
    Peter Schmid
    Mark R. Lackner
    Nature Communications, 7
  • [43] Monitoring of PIK3CA and ESR1 mutations in circulating tumor DNA as predictive and prognostic biomarkers in patients with endocrine-resistant ER+/HER2-advanced breast cancer.
    Fuentes Antras, Jesus
    Garcia-Barberan, Vanesa
    Gonzalo, Irene
    Moreno, Fernando
    Lopez-Cade, Igor
    Ramirez-Ruda, Carmen
    Bueno, Oskia
    Ascaso del Rio, Ana
    Pascual, Alejandro
    Ocana, Alberto
    Caldes, Trinidad
    Angel Garcia-Saenz, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Using real-world data to evaluate the performance of endocrine therapies in ER+/Her2-metastatic breast cancer patients.
    Chen, Tenghui
    Zhang, Zhaojie
    Gao, Lei
    Scholz, Catherine
    Gualberto, Antonio
    Yu, Lihua
    Yu, Kun
    CANCER RESEARCH, 2022, 82 (12)
  • [45] ESR1 genomic alterations (GAs) and coexistent putative resistance alterations in comprehensive genomic profiling (CGP) of metastatic breast cancer (MBC)
    McArthur, Heather
    Tukachinsky, Hanna
    Schrock, Alexa
    Madison, Russell
    Holmes, Oliver
    Sivakumar, Smruthy
    Sokol, Ethan
    Graf, Ryon
    Quintanilha, Julia
    Dougherty, Kali
    Pasquina, Lincoln
    Oxnard, Geoffrey
    Levy, Mia
    Winer, Eric
    CANCER RESEARCH, 2024, 84 (09)
  • [46] Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2-metastatic breast cancer (mBC).
    Bardia, Aditya
    Linden, Hannah M.
    Ulaner, Gary A.
    Chandarlapaty, Sarat
    Gosselin, Alice
    Doroumian, Severine
    Celanovic, Marina
    Campone, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] ASSESSMENT OF EARLY PROGRESSION RISK FOR PATIENT WITH ESR1 MUTATIONS AND HORMONE RECEPTOR POSITIVE (HR+)/ HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Tarasenko, Tetiana
    Syvak, Liubov
    Martyniuk, Olena
    Bondar, Maryna
    BREAST, 2023, 71 : S52 - S53
  • [48] Elacestrant vs standard-of-care in ER+/HER2-advanced or metastatic breast cancer (mBC) with ESR1 mutation: key biomarkers and clinical subgroup analyses from the phase 3 EMERALD trial
    Bardia, Aditya
    O'Shaughnessy, Joyce
    Bidard, Francois-Clement
    Neven, Patrick
    Garcia-Saenz, Jose Angel
    Aftimos, Philippe
    Cortes, Javier
    Lu, Janice
    Tonini, Giulia
    Theall, Kathy Puvana
    Paoli, Alessandro
    Kaklamani, Virginia
    CANCER RESEARCH, 2024, 84 (09)
  • [49] Elacestrant vs Standard-of-Care in ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) With ESR1 Mutation: Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01)
  • [50] Circulating tumor DNA analysis for ESR1 mutations in patients with hormone receptor-positive metastatic breast cancer
    Sim, Sung Hoon
    Jeon, Su Yeon
    An, Kyoung Hee
    Kong, Sun Young
    Kwon, Min Jung
    Lee, Keun Seok
    Park, In Hae
    CANCER RESEARCH, 2018, 78 (13)
12345